Fostamatinib significantly reduced serious adverse effects and risk of death in hospitalised COVID-19 patients, shows Phase II study.
List view / Grid view
National Heart Lung and Blood Institute (NHLBI)
Clinical trial shows that treating moderately ill COVID-19 patients with a full-dose blood thinner reduced their need for organ support.
The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.
The generic Proventil HFA (albuterol sulfate) metered dose inhaler has been approved for the prevention of bronchospasm in patients four years of age and older.
Treatments for psoriasis could help prevent heart disease in patients with the skin condition, with patients having an 8 percent reduction in their risk...
Researchers have discovered that genetic variations in the anatomy of the lungs could serve as indicators to help identify people who are particularly at risk for COPD...